Merck details an immunotherapy 'milestone' in early breast cancer
Bio Pharma Dive
JULY 15, 2021
Three months after a rare FDA rejection, Merck has data showing Keytruda can slow the return of triple-negative breast cancer but not, as of yet, proving whether the drug extends lives.
Let's personalize your content